Does Prostate Radiation Cause Erectile Dysfunction?

Prostate radiation does cause erectile dysfunction in a substantial number of men, though the risk is lower and the onset more gradual than with surgery. A large meta-analysis estimated that about a third of men have confirmed ED one year after radiation, rising to roughly 57% by five and a half years.¹ The gradual nature of the decline is what catches many men off guard, because erections often seem fine in the first months after treatment before slowly worsening over the next few years.

How Common Is It, and When Does It Start

Unlike surgery, which can damage the nerves controlling erections immediately, radiation-induced ED develops over months to years. Most studies put the five-year rate at roughly half of all treated men, though estimates range depending on how strictly ED is defined and how good a man’s erections were before treatment.² A prospective European study that tracked men through treatment and beyond found that the ability to have any erection dropped from about 81% before radiation to 60% at last follow-up, while the ability to have erections firm enough for intercourse fell from 44% to 27%.³ Those numbers kept drifting downward over time, meaning a man who feels fine at one year is not necessarily in the clear.

The timeline matters for expectations. Erectile function scores in that same study had already dropped by the end of the radiation course itself, suggesting some early effects, but the steeper decline came in the one-to-three-year window. One study of younger patients (age 60 and under) found that 73% reported no or only minimal decline at two years, which sounds encouraging until you consider that the five-year picture is bleaker.⁴ The practical takeaway is that early reassurance from your radiation oncologist about preserved function is not the final word. You need to keep monitoring, ideally for at least five years.

What Radiation Actually Does to Erectile Tissue

The mechanism is not a simple on-off switch. Radiation damages two systems that erections depend on: the blood vessels feeding the penis and the nerves that trigger the process. Animal studies have shown that after prostate irradiation, the arteries inside the penile tissue develop thickened walls, lose smooth-muscle cells, and can become partially blocked.⁵ Essentially, the pipes narrow. At the same time, the cavernous nerves that run alongside the prostate show progressive damage: their insulating myelin coating breaks down, the nerve fibers shrink, and the speed of nerve signals drops.⁶

One research group tried to tease apart which injury matters more. They used a drug that protected blood vessels but not nerves, and found that while vascular protection preserved the arteries’ ability to dilate, it did not fix the nerve damage.⁷ This suggests that both systems need to be intact for erections to work, and that protecting just one is not enough. It also helps explain why the decline is gradual: vascular damage and scarring accumulate slowly, and nerve deterioration compounds over time rather than happening all at once.

Risk Factors That Shift Your Odds

Not every man who gets prostate radiation will lose his erections. Several factors tilt the odds in a predictable direction. A systematic review identified the key determinants as age, how well your erections work before treatment, existing health conditions like diabetes and cardiovascular disease, whether you also receive hormone therapy, and how much radiation dose reaches the erectile structures near the prostate.⁸

Of these, baseline erectile function is probably the strongest single predictor. The European study mentioned earlier found that the correlation between pre-treatment function and late function was strong, and that men who reported regular nighttime erections before treatment had dramatically better odds of keeping functional erections afterward. Men with at least weekly nighttime erections were nearly six times more likely to maintain erections sufficient for intercourse than those with less frequent ones.³ Age and diabetes also predicted both pre-existing ED and post-radiation ED in that same analysis.

Age deserves emphasis on its own. In a study of stereotactic body radiation therapy (a newer, high-dose-per-session approach), 60% of men under 70 maintained satisfactory erectile function, compared with only 12% of men 70 and older.⁹ That gap is enormous. A 55-year-old and a 72-year-old facing the same radiation plan are really facing different risk profiles.

Does the Type of Radiation Matter

Men often wonder whether choosing brachytherapy (radioactive seeds implanted in the prostate) or stereotactic body radiation therapy over conventional external-beam radiation will spare their erections. The evidence is surprisingly consistent: the rates end up in the same ballpark regardless of modality.

Brachytherapy causes ED in roughly half of men within three to five years of implantation. The radiation dose reaching the base of the penis (the proximal crura) was the strongest treatment-related predictor of ED in one large brachytherapy study.¹⁰ The same risk factors apply here as elsewhere: older age, diabetes, and supplemental external-beam radiation on top of the seeds all make things worse.¹¹

Stereotactic body radiotherapy (SBRT), which delivers fewer sessions at higher doses, has attracted attention partly because it is more convenient and partly because some hoped its precision might spare erectile tissue. The data shows that roughly 45% to 57% of men with functional erections at baseline retain them two to five years out.¹² One study specifically compared SBRT outcomes to model-predicted outcomes for conventional external-beam and brachytherapy and found no statistical difference across the board.¹² Another SBRT study reported that sexual potency declined steadily through the first year and then plateaued, with about 56% remaining potent.¹³

The practical implication is that choosing a radiation type for the purpose of protecting erections is unlikely to help. Your baseline function, age, and whether hormone therapy is added matter far more than whether you get seeds, stereotactic treatment, or standard external-beam.

When Hormone Therapy Is Added

Many men with intermediate- or high-risk prostate cancer receive androgen deprivation therapy (ADT) alongside radiation. ADT suppresses testosterone, which directly reduces sex drive and can impair erections through hormonal and vascular pathways. The combination of radiation plus hormone therapy significantly impairs erectile function beyond what radiation alone causes.¹⁴

A study of men receiving intensity-modulated radiation found that those on ADT had worse sexual scores at two and six months compared with men who got radiation alone. By 24 months, the gap in overall sexual scores had closed, but men on ADT were still less likely to be sexually active. The duration of ADT was the factor that mattered most: longer courses meant worse outcomes.¹⁵ Short-term ADT (a few months) caused less lasting damage than long-term courses. A population-based study found that men treated with external-beam radiation plus ADT had preservation rates of useful sexual function between about 8% and 52% at two years, compared with 14% to 71% for radiation alone.¹⁶

If you are told you need ADT, ask your oncologist about the expected duration. For some risk categories, shorter courses may offer similar cancer control with less sexual toxicity. This is a conversation worth having early, before treatment starts.

How Radiation Compares with Surgery

Men newly diagnosed with localized prostate cancer often want to know whether surgery or radiation is easier on their sex life. The picture is more nuanced than “one is better.” Surgery tends to cause immediate, steep declines in erectile function because the nerves next to the prostate are at high risk of injury during removal. Radiation causes a slower, more gradual decline. One older study found no significant difference in post-treatment erectile function between men who had radical prostatectomy and those who had external-beam radiation, with roughly 10% and 15% retaining good function respectively.¹⁷

The population-based prospective study described above reported a wider range of outcomes depending on the specific technique. Nerve-sparing surgery preserved useful sexual function in roughly 5% to 45% of men at two years, while external-beam radiation alone preserved it in about 14% to 71%, with the wide ranges reflecting differences in age and baseline function.¹⁶ The observational nature of these studies makes direct comparisons imperfect, as the men selecting each treatment often differ in age, health, and cancer severity.¹⁸ The honest answer is that both treatments carry serious risk to erections, with the pattern and timing differing more than the final outcome for most men.

Keeping Dose Away from Sensitive Structures

Radiation oncologists can try to protect erectile tissue by carefully shaping the radiation beams. The penile bulb, the crura (the internal arms of the penis where it attaches to the pelvic bones), and the internal pudendal arteries are the structures that matter most. Guidelines have recommended keeping the mean dose to 95% of the penile bulb below 50 Gy, with additional limits on higher doses to smaller portions of the structure.¹⁹

More recent data from the CHHiP trial suggested that the real threshold for penile bulb dose and ED risk may be considerably lower, around 20 Gy mean dose, which is substantially below the older guidelines.²⁰ If confirmed, this means many radiation plans that technically met the old limits were still delivering enough dose to erectile tissue to increase risk. Not every treatment center may be using the more aggressive dose-sparing approach, so this is worth asking your radiation oncologist about.

Interestingly, a randomized phase 2 trial of urethra-sparing SBRT found no statistically significant difference in the dose reaching the penile bulb or internal pudendal arteries between men who developed ED and those who did not.²¹ This hints that dose to identifiable structures may not be the entire story, and that more subtle tissue-level damage or individual susceptibility plays a role the current planning tools cannot fully account for.

One physical innovation that has shown some promise is a hydrogel spacer placed between the prostate and the rectum. Though designed primarily to reduce rectal side effects, a secondary analysis of a phase 3 trial found that among men with adequate baseline sexual function, those who received the spacer were more likely to maintain erections sufficient for intercourse at three years (about 67% vs. 38% in the control group).²² The mechanism is likely indirect: by pushing the rectum away, the spacer may allow tighter radiation beams that incidentally spare some erectile tissue.

Treating ED After Radiation

The first-line treatment for radiation-induced ED is the same class of medications used for any ED: PDE5 inhibitors like tadalafil (Cialis), sildenafil (Viagra), and similar drugs. A randomized trial comparing on-demand tadalafil at 20 mg with daily 5 mg tadalafil in men with post-radiation ED found that both dosing schedules produced meaningful improvements in erectile function, with the majority of men reporting successful intercourse attempts. The daily low-dose regimen had slightly higher compliance and fewer side effects.²³ An earlier open-label extension study also confirmed that tadalafil was effective in many post-radiation ED patients, with improvements across most sexual function domains.²⁴

What about using these medications preventively, starting them during or right after radiation to head off ED before it takes hold? A well-designed randomized trial tested exactly this, giving daily tadalafil or placebo during and shortly after radiation. The result was disappointing: about 79% of men on tadalafil retained erectile function compared with 74% on placebo, a difference that was not statistically significant. At one year, the groups were essentially identical.²⁵ So while PDE5 inhibitors are useful for treating ED once it develops, the idea of taking them prophylactically to prevent it has not panned out in a rigorous trial.

Beyond pills, penile rehabilitation programs that combine PDE5 inhibitors, vacuum erection devices, and sometimes penile injections have shown promise in improving erectile function after prostate cancer treatment, though the optimal timing and duration are still being studied.²⁶ A separate systematic review specifically focused on men receiving radiation and ADT confirmed the value of starting PDE5 inhibitors early and identified a need for ongoing use during hormone therapy.²⁷ The general consensus is that doing something to maintain blood flow to erectile tissue is better than waiting until the damage is fully established, even if the evidence for any single approach is still evolving.

The Sexual Side Effects Beyond Erections

ED gets most of the attention, but radiation affects other aspects of sexual function that men are often unprepared for. Ejaculatory disturbances, including reduced semen volume, absent ejaculation, pain during ejaculation, and blood in the semen, have been reported in anywhere from 2% to 56% of men after prostate radiation. Dissatisfaction with sex life varies from 25% to 60%, and loss of sexual desire affects between 12% and 58%.⁴ These ranges are wide because the studies varied in how they measured symptoms and how long they followed patients, but the point is that the sexual impact of radiation is broader than just losing erections. Many men find the changes in ejaculation distressing even when their erections remain adequate, and the combination of reduced desire, altered sensation, and mechanical difficulty can erode sexual quality of life in ways that a single ED questionnaire does not fully capture.

Genetic Prediction of Radiation-Induced ED

One of the more intriguing research directions is the attempt to predict who will develop radiation-induced ED before treatment even starts. A genome-wide association study identified 12 genetic variants associated with developing ED after radiation. These variants were not in DNA-repair genes, as you might expect, but in genes involved in erectile function itself, cell adhesion, and signaling. Men carrying more of these risk variants had dramatically higher odds of developing ED: each additional risk variant roughly doubled a man’s odds. The genetic model had about 84% sensitivity and 75% specificity for predicting ED at the treatment-planning stage.²⁸

Building on this foundation, researchers have developed a deep-learning model that combines genetic data with clinical variables like age and ADT use. In test data, the model achieved an area under the curve of 0.75, and men in the highest predicted risk group had nearly 12 times the odds of developing ED compared with those in the lowest risk group. The biological pathways driving the predictions included neurological processes, reproductive hormone regulation, and blood vessel development, which lines up neatly with what we know about how the damage actually occurs.²⁹

None of this is clinically available yet. You cannot walk into a radiation oncology clinic and get a genetic test that tells you your personal ED risk. But the research suggests that within the next decade, treatment planning could incorporate individual genetic vulnerability alongside standard factors like age and baseline function. For men who are genetically high-risk, that information could change how aggressively dose is sculpted away from erectile structures, or even tilt the choice between treatment options. For low-risk men, it might provide genuine reassurance that is currently impossible to give.

Emerging Therapies on the Horizon

Current treatments for radiation-induced ED essentially work around the damage rather than reversing it. PDE5 inhibitors help the remaining functional tissue respond better, vacuum devices mechanically assist blood flow, and injections bypass the nerve-signaling problem entirely. But none of them repair the scarred arteries or restore the degraded nerve fibers.

Stem cell therapy is the approach most researchers are watching. In animal models where rats received prostate radiation, injection of stem cells into the penile tissue improved erectile function.³⁰ Low-intensity shockwave therapy, which uses acoustic waves to stimulate blood vessel growth, is another approach under investigation for post-cancer ED. The evidence remains early-stage and largely limited to small studies and case series. Neither approach is ready for routine clinical use, but they represent a fundamentally different strategy from what is currently available: attempting to regenerate the damaged tissue rather than compensating for it. For men who do not respond adequately to PDE5 inhibitors or find injections and devices unsatisfying, these experimental therapies offer at least a direction worth following in the research literature over the coming years.